November 12, 2020
La Jolla, California--(Newsfile Corp. - November 12, 2020) - Tryp Therapeutics, a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announced today it has appointed Dr. Jim Gilligan as President and Chief Scientific Officer.
Dr. Gilligan brings over 30 years of drug development activities including pharmacology, preclinical activities, CMC manufacturing, clinical phase I-III, as well as US and international regulatory strategies. A tangible result of this broad-based experience is reflected in the fact that he was a co-founder of Unigene Laboratories, the first company to have a recombinant peptide product (Fortical®) approved by the FDA via the 505(b)(2) NDA route.
Dr. James Kuo, MD, MBA, Tryp's CEO states, "We are fortunate to have found someone of Dr. Gilligan's vast experience in drug development and regulatory expertise. His particular knowledge in 505(b)(2) NDA drug development will be critical in the advancement of our two drug programs, which have a similar regulatory strategy. We couldn't be more excited to welcome him to our team."
Jim transitioned from research and development to business development and during this time obtained a Masters in International Business from Seton Hall University. As VP Product and Business Development, he established a biotech joint venture which led to him co-founding Herborium Inc., a company involved in the development of Botanical Therapeutics™.
Mr. Gilligan was responsible for executing numerous feasibility and licensing deals with the pharma industry. As part of his business development responsibilities he worked frequently with investment bankers, venture capitalists, and investment advisors. Additionally, Jim was a co-founder and CSO of Tarsa Therapeutics that completed the phase III ORACAL study as well the NDA submission for TBRIA an oral formulation of recombinant salmon calcitonin for the treatment of postmenopausal osteoporosis.
Dr. Jim Gilligan, President and CSO states, "I am excited to join this team of seasoned bio-executive professionals dedicated to bringing forward innovative drug candidates addressing diseases with significant unmet medical needs. To be at the forefront of this new and emerging psychedelic renaissance in biotech and drug development provides a unique opportunity to continue the groundbreaking research surrounding psychedelics and explore the potential of Psilocybin in the treatment of a wide range of serious diseases."
Dr. Gilligan received his PhD in Pharmacology and Toxicology from the University of Connecticut where his research focus was cardiovascular disease, in particular atherosclerosis. He continued his post graduate education at the Roche Institute of Molecular Biology where his post-doctoral research explored changes that occur in blood vessels during the development of hypertension.
About Tryp Therapeutics:
Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds. It is led by a management team with extensive drug development experience that is advancing transformative medicines with existing clinical data and known safety profiles for diseases with no effective first-line treatments. The company is building a diversified portfolio of product candidates targeting neuropsychiatric and oncology indications with high unmet medical needs.
This news release contains forward-looking information relating to the Company's proposed activities and other statements that are not historical facts. Forward-looking information relates to management's future outlook and anticipated events or results and includes statements or information regarding the future plans or prospects of the Company. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. These factors include risks and uncertainties associated with or arising as a result of delays in obtaining or an inability to obtain required regulatory approvals, access to sufficient quantities of cannabis, the results of diligence investigations, the actions of third parties, the results of negotiations with third parties, developments in the cannabis sector, the ability to access sufficient capital from internal and external sources, reliance on key personnel, regulatory risks and delays and other risks and uncertainties discussed in the management discussion and analysis section of the Company's interim and most recent annual financial statement or other reports and filings, including those made with the CSE and applicable Canadian securities regulators. There can be no assurance that such forward looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information.